Clinical Trial

Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment. After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-22.
Trial Details
NCT Number NCT06571214
Lead Sponsor Nanjing University
Conditions Infertility
Enrollment 300 participants
Start Date 2024-09-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-27